Core Viewpoint - Rosen Law Firm is reminding investors who purchased Inovio Pharmaceuticals, Inc. securities between October 10, 2023, and December 26, 2025, of the April 7, 2026, deadline to become lead plaintiffs in a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Inovio securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court by April 7, 2026, to serve as lead plaintiff [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [4]. Group 2: Case Allegations - The lawsuit alleges that defendants made false and misleading statements regarding Inovio's CELLECTRA device manufacturing and the likelihood of submitting the INO-3107 Biologics License Application to the FDA by the second half of 2024 [5]. - It is claimed that Inovio lacked sufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review, leading to overstated regulatory and commercial prospects [5]. - The lawsuit asserts that when the true details became public, investors suffered damages due to the misleading statements made by the defendants [5].

Core Insights - XORTX Therapeutics Inc. is a late-stage clinical pharmaceutical company focused on innovative therapies for gout and progressive kidney disease [1] - The company held its annual and special meeting of shareholders on March 24, 2026, where all proposed matters were approved [2] Company Overview - XORTX has three clinically advanced products: XRx-026 for gout, XRx-008 for autosomal dominant polycystic kidney disease (ADPKD), and XRx-101 for acute kidney injury related to respiratory virus infections [3] - Additionally, the company is developing XRx-225, a pre-clinical program targeting Type 2 diabetic nephropathy [3] - The company aims to improve the quality of life for individuals with gout and other significant diseases by targeting purine metabolism and xanthine oxidase to reduce uric acid production [3] Shareholder Meeting Outcomes - A total of 2,407,148 common shares were represented at the meeting, accounting for approximately 35% of the total shares issued and outstanding [2] - All five management nominees were elected to the board of directors, and Davidson & Company LLP was appointed as auditors for the upcoming year [2] - The stock option plan was re-approved, and a share consolidation was authorized [2]

Financial Data and Key Metrics Changes - For Q4 2025, the company generated total revenues of $2.8 million, with net product revenues of $2.5 million from ZUNVEYL, and total revenues for the full year reached $10.2 million, including $6.8 million from ZUNVEYL [17][18] - Operating expenses for Q4 were $10.7 million, compared to $2.7 million in Q4 2024, leading to an operating loss of $7.9 million for the quarter [18][19] - The net loss for Q4 2025 was $6.9 million, or $0.30 per share, compared to a net loss of $5.8 million, or $0.52 per share in the same period last year [19][20] Business Line Data and Key Metrics Changes - ZUNVEYL's sales growth was highlighted, with 4,941 bottles dispensed in Q4, marking a 62% quarter-over-quarter growth [22] - The number of prescribing doctors increased by 50% compared to Q3, and cumulative homes with prescriptions rose by 69% in Q4 [10] Market Data and Key Metrics Changes - The company has signed contracts with two of the four major PBMs, enhancing payer access, which is crucial for market penetration [10][11] - The company is focused on expanding its reach in the $2 billion long-term care market, where ZUNVEYL is positioned as a treatment option [6][15] Company Strategy and Development Direction - The company aims to achieve operational profitability by 2027 while expanding ZUNVEYL's market presence and enhancing payer engagement strategies [7][16] - The company is initiating three real-world studies in 2026 to strengthen ZUNVEYL's positioning with payers and healthcare providers [7][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in ZUNVEYL's adoption trajectory, emphasizing the importance of repeat ordering behavior and provider confidence as indicators of sustained performance [9][10] - The company expects continued sequential growth in ZUNVEYL sales through 2026 as physician awareness increases and payer access expands [21] Other Important Information - The company raised $40 million in Q3 2025, which has been allocated to expand its commercial reach and payer engagement strategies [7][16] - The company maintains a strong financial position with approximately $66 million in unrestricted cash as of December 31, 2025 [20][21] Q&A Session Summary Question: Timing for conversion of additional payers and promotion into neurologist prescriber base - Management expects to see some acceleration in Q2 for regional plans, with significant pickup in Q3, and plans to expand into neurology as they approach profitability in 2027 [31][33] Question: Key takeaways from the CONVERGE study - The study will evaluate polypharmacy and is expected to provide data that will be crucial for positioning ZUNVEYL with health plans and providers [35][36] Question: Clinical development timeline for the sublingual formulation - The company plans to initiate a PK comparative study in 2026, with potential entry into the clinic in early 2027, depending on data outcomes [40][41] Question: Sales rep expansion and inflection points - The sales force expansion is complete, and management believes this will significantly accelerate business growth [53][54] Question: Changes in marketing strategy for ZUNVEYL - The company has shifted its messaging to emphasize behavioral improvements alongside tolerability, which has broadened its prescriber base [61][62] Question: Aspirational outlook for the BEACON study - The BEACON study aims to demonstrate strong cognitive effects and tolerability for ZUNVEYL, which will be important for provider and payer engagement [65][66]

Core Insights - Journey Medical Corporation reported revenue of $16.08 million for the quarter ended December 2025, marking an 18.1% year-over-year increase, but fell short of the Zacks Consensus Estimate by 15.68% [1] - The company reported an EPS of -$0.04, which is an improvement compared to $0.08 a year ago, resulting in a positive EPS surprise of 27.27% against the consensus estimate of -$0.06 [1] Revenue Breakdown - Total net product revenue from Accutane was $3.06 million, exceeding the average estimate of $2.77 million, but reflecting a year-over-year decline of 20.9% [4] - Total net product revenue from EmrosiTM was $5 million, significantly lower than the estimated $7.42 million [4] - Total net product revenue from Qbrexza was $5.54 million, also below the estimated $6.97 million, with a year-over-year change of -2.4% [4] Stock Performance - Journey Medical's shares have decreased by 21.7% over the past month, contrasting with a 5% decline in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Financial Data and Key Metrics Changes - For Q4 2025, the company generated total revenues of $2.8 million, with net product revenues of $2.5 million from ZUNVEYL, and total revenues for the full year reached $10.2 million, including $6.8 million from ZUNVEYL [16][17] - Operating expenses for Q4 were $10.7 million, compared to $2.7 million in Q4 2024, leading to an operating loss of $7.9 million for the quarter, versus $2.7 million in the same period last year [17][18] - The net loss for Q4 2025 was $6.9 million, or $0.30 per share, compared to a net loss of $5.8 million, or $0.52 per share in Q4 2024 [18][19] Business Line Data and Key Metrics Changes - ZUNVEYL's sales growth continued, with 4,941 bottles dispensed in Q4, marking a 62% quarter-over-quarter growth, and December alone saw 1,859 bottles dispensed, the strongest month since launch [21][22] - The number of prescribers increased by 50% compared to Q3, and cumulative homes with prescriptions rose by 69% in Q4, indicating expanding adoption [10][22] Market Data and Key Metrics Changes - The company has signed contracts with two of the four major pharmacy benefit managers (PBMs), enhancing payer access and coverage for ZUNVEYL [10][11] - The company is focused on expanding its reach in the $2 billion long-term care market, where ZUNVEYL is positioned to address symptom management and behavioral issues associated with Alzheimer's [5][14] Company Strategy and Development Direction - The company aims to achieve operational profitability by 2027, supported by ongoing investments in commercial infrastructure and payer engagement strategies [6][15] - The focus for 2026 includes expanding penetration per home, deepening prescriber relationships, and accelerating payer pull-through [25][28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the underlying demand indicators for ZUNVEYL, emphasizing the importance of repeat ordering behavior and provider confidence as predictors of sustained performance [9][10] - The company anticipates continued sequential growth in ZUNVEYL sales through 2026 as physician awareness increases and payer access expands [20][21] Other Important Information - The company raised $40 million in Q3 2025, which has been allocated to expand its commercial reach and support marketing efforts for ZUNVEYL [6][15] - Three real-world studies are set to be initiated in 2026 to provide further evidence of ZUNVEYL's efficacy and tolerability [12][13] Q&A Session Summary Question: Timing for conversion of additional payers and promotion into neurologist prescriber base - Management expects to see some acceleration in Q2 for regional plans, with significant pickup in Q3, and plans to expand into neurology as they approach profitability in 2027 [30][31] Question: Key takeaways from the CONVERGE study - The study will evaluate polypharmacy and is expected to provide data on adherence, tolerability, and consistency, which will be crucial for positioning ZUNVEYL in the market [34][35] Question: Clinical development timeline for the sublingual formulation - A PK comparative study will be initiated, and if successful, the sublingual formulation could enter the clinic in early 2027 [39][40] Question: Sales rep expansion and inflection points - The sales force expansion is complete, and management believes this will significantly accelerate business growth [52][53] Question: Changes in marketing strategy for ZUNVEYL - The company has shifted its messaging to emphasize behavioral benefits alongside tolerability, which has broadened its prescriber base [59][60] Question: Aspirational outlook for the BEACON trial - The BEACON study aims to demonstrate strong cognitive effects and tolerability for ZUNVEYL, which is crucial for market positioning [63][64]

Core Insights - Novo Nordisk experienced a transformative year in 2025, particularly in the diabetes and obesity markets, leading to unprecedented growth that exceeded expectations [1][2] - The company has recognized that individuals with obesity face different challenges compared to those with diabetes, necessitating a shift in approach to patient care and market access [2][3] - The competitive landscape in the obesity market has evolved significantly, with major pharmaceutical companies now acknowledging the importance of this therapeutic area [3] Company Strategy - Novo Nordisk's entry into the obesity market has been characterized by a focus on meeting the needs of patients who often experience shame and stigmatization, rather than fear as seen in diabetes patients [2] - The company is adapting its traditional physician-focused model to better address the unique challenges faced by individuals with obesity, emphasizing discretion and patient-centered care [2][3] - The demand for obesity medications has led to a shift in market dynamics, with self-paying consumers seeking faster access to treatments [2] Market Dynamics - The growth in the obesity market has brought global attention to Novo Nordisk's operations, highlighting the need for innovative approaches to patient engagement and treatment accessibility [2] - The evolving competitive landscape indicates that Novo Nordisk must continuously adapt to maintain its leadership position in the obesity market [3]

Core Viewpoint - XORTX Therapeutics Inc. has delayed its share consolidation from March 27, 2026, to April 6, 2026, pending necessary approvals from the TSX Venture Exchange and Nasdaq Stock Exchange [1] Company Overview - XORTX is a late-stage clinical pharmaceutical company focused on developing therapies for gout and progressive kidney disease [2] - The company has three clinically advanced products: 1. XRx-026 for gout treatment 2. XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD) 3. XRx-101 for acute kidney injury related to respiratory virus infections - Additionally, XORTX is developing XRx-225, a pre-clinical program for Type 2 diabetic nephropathy [2] - The company aims to target aberrant purine metabolism and xanthine oxidase to reduce uric acid production [2]

CORPORATE DECK MARCH 26, 2026 DAREBIOSCIENCE.COM | NASDAQ: DARE ©2026 DARÉ BIOSCIENCE, ALL RIGHTS RESERVED Forward-Looking Statements & Disclaimers This presentation is for informational purposes only and is not an offer to sell or a solicitation of an offer to buy any securities of Daré Bioscience, Inc. ("Daré" or the "Company"). This presentation discusses potential future drug and medical device products that are or will be under clinical or preclinical investigation and have not been approved for use ou ...

Core Insights - Shuttle Pharmaceuticals Holdings, Inc. has made significant advancements to its molecule.ai platform, enhancing its capabilities in therapeutic discovery and positioning the company as a leader in AI-driven drug development [1][5] Group 1: Platform Enhancements - The latest release introduces new models that allow users to evaluate, prioritize, and advance therapeutic candidates more effectively, transitioning from fragmented data analysis to a scalable, end-to-end solution for therapeutic development [2][3] - The platform now features a sophisticated reasoning system that can identify and prioritize relationships between genes and disease pathways, as well as predict compound interactions with specific biological targets, thus improving the evaluation of therapeutic opportunities [3] Group 2: Autonomous AI Agent System - The company has previewed a next-generation autonomous AI agent system that enables multi-step reasoning and multi-agent orchestration across complex scientific workflows, significantly reducing manual effort and increasing throughput for research teams [4] Group 3: Strategic Vision - The CEO of Shuttle Pharma emphasized that the integration of reasoning, prediction, and automation into a single platform could materially reduce timelines, lower costs, and increase the probability of success in drug development, positioning the company for leadership in AI-powered biopharma innovation [5] - The company aims to build a scalable platform that unlocks new therapeutic opportunities, improves development efficiency, and creates long-term value for shareholders [5][6]

Core Viewpoint - Crinetics Pharmaceuticals has submitted a Marketing Authorization Application (MAA) for PALSONIFY™ (paltusotine) to Brazil's National Health Surveillance Agency (ANVISA) for the treatment of acromegaly in adults, marking a significant global milestone for the therapy [1][2]. Group 1: Product Development and Approval - PALSONIFY is the first once-daily, oral, selectively-targeted somatostatin receptor type 2 nonpeptide agonist approved in the US for adults with acromegaly who had an inadequate response to surgery or for whom surgery is not an option [3][6]. - The MAA submission is supported by data from 18 clinical trials, including two Phase 3 trials where all primary and secondary endpoints were met, demonstrating significant biochemical control and symptom management compared to placebo [2][4]. - In Europe, Crinetics has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) regarding the MAA for PALSONIFY for treating acromegaly in adults [3]. Group 2: Clinical Trial Results - In Phase 3 studies, PALSONIFY maintained IGF-1 levels and symptom control in patients switched from monthly injectable medications and rapidly decreased IGF-1 levels in untreated acromegaly patients [4]. - Paltusotine is also in Phase 3 clinical development for carcinoid syndrome associated with neuroendocrine tumors, with Phase 2 study results showing rapid and sustained reductions in flushing episodes and bowel movement frequency [4][6]. Group 3: Company Overview - Crinetics Pharmaceuticals is focused on transforming the treatment of endocrine diseases and related tumors, with expertise in developing novel therapies targeting G-protein coupled receptors (GPCRs) [5]. - The company has a pipeline of over 10 disclosed programs, including late-stage candidates for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome, as well as other endocrine conditions [6].